The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

Transcarent CEO Glen Tullman previously led Livongo, which was purchased by Teladoc in a 2020 agreement that valued the ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

4.6-star analyst Allen Lutz said that tirzepatide likely won’t bring in much money for Hims, especially since Eli Lilly sells it for $500 per month on its own platform, while Hims lists it at a ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

AI fundraises, tech partnerships and M&A deals, including DispatchHealth and Medically Home's tie-up, and plans for a ...

Companies like Hims & Hers and WeightWatchers have been ... approved, and studied Zepbound for patients who are being asked to pay out-of-pocket," he added. Jonsson also told Reuters that more ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023 ... with shares of Hims & Hers Health, a company offering compounded versions of GLP-1 treatments ...